Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric GI-aGvHD
2025-524302-15-00Phase 2Authorised
- Sponsor
- MaaT Pharma
- Start
- Apr 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of MaaT013 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by MaaT Pharma. Primary endpoints: Incidence of treatment-emergent adverse events, serious adverse events, and safety parameters, Incidence of serious adverse events and adverse events of special interest and 5 more. Planned start Apr 2026; status: authorised.
02
Drugs
MaaT013
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2025-524302-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524302-15-00.